OpenVirtualToxLab-A platform for generating and exchanging in silico toxicity data

Toxicology Letters

Volumn 232, Issue 2, 2015, Pages 519-532

  Vedani, Angelo ^a,b   Dobler, Max ^b   Hu, Zhenquan ^a   Smieško, Martin ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Biographics Laboratory 3R   (Switzerland)

Author keywords

3D simulations; In silico toxicology; Mechanistic interpretation; Open access platform; Protein mediated adverse effects

Indexed keywords

ANDROGEN RECEPTOR; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLUCOCORTICOID RECEPTOR; LIVER X RECEPTOR; MINERALOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POTASSIUM CHANNEL; PROGESTERONE RECEPTOR; THYROID RECEPTOR ALPHA; THYROID RECEPTOR BETA; UNCLASSIFIED DRUG; CARCINOGEN; CARDIOTOXIN; CELL RECEPTOR;

ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; COMPUTER INTERFACE; COMPUTER MODEL; OPENVIRTUALTOXLAB; PROTEIN BINDING; SIMULATION; TECHNOLOGY; TOXICITY; ANIMAL; COMPUTER PROGRAM; DRUG EFFECTS; HUMAN; INFORMATION DISSEMINATION; INTERNET; PROCEDURES; PROTEIN CONFORMATION; TOXICOLOGY; TRENDS;

ANIMALS; CARCINOGENS; CARDIOTOXINS; HUMANS; INFORMATION DISSEMINATION; INTERNET; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SOFTWARE; TOXICOLOGY;

EID: 84918807466     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.09.004     Document Type: Article

References (68)

1. Amini A., Mugleton S.H., Lohdi H., Sternberg M.J.E. A novel logic-based approach for quantitative toxicology prediction. J. Chem. Inf. Model. 2007, 47:998-1006.
2. Aronov A.M., Balakin K.V., Kiselyov A., Varma-O'Brien S., Ekins S. Application of QSAR to ion channels. Computational Toxicology-Risk Assessment for Pharmaceutical and Environmental Chemicals 2007, 353-390. John Wiley & Sons, New York, USA. S. Ekins (Ed.).
3. Aronov A.M. Predictive in silico models for hERG channel blockers. Drug Discov. Today 2005, 10:149-155.
4. Bars R., Broeckaert F., Fegert I., Gross M., Hallmark N., Kedwards T., Lewis D., O'Hagan S., Panter G.H., Weltje L., Weyers A., Wheeler J.R., Galay-Burgos M. Science based guidance for the assessment of endocrine-disrupting properties of chemicals. Reg. Toxicol. Pharmacol. 2011, 59:37-46.
5. Bender A., Scheiber J., Glick M., Davies J.W., Azzaoui K., Hamon J., Urban L., Whitebread S., Jenkins J.L. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2007, 2:861-873.
6. Benfenati E., Begigni R., DeMarini D.M., Helma C., Kirkland D., Martin T.M., Mazzatorta P., Quédraogo-Arras G., Richard A.M., Schilter B., Schoonen W.G.E.J., Snyder R.D., Yang C. Predictive models for carcinogenicity and mutagenicity: frameworks state-of-the-art, and perspectives. J. Env. Sci. Health Part C. Environ Carcinog. Ecotoxicol. Rev. 2009, 27:57-90.
7. Biedermann S., Zurfluh M., Grob K., Vedani A., Brüschweiler B.J. Migration of cyclo-diBA from coatings into canned food: method of analysis: concentration determined in a survey and in silico hazard profiling. Food Chem. Tox. 2013, 58:107-115.
8. Bowers K.J., Chow E., Xu H., Dror R.O., Eastwood M.P., Gregersen B.A., Klepeis J.L., Kolossváry I., Moraes M.A., Sacerdoti F.D., Salmon J.K., Shan Y., Shaw D.E. Proceedings of the 2006 ACM/IEEE Conference on Supercomputing Table of Contents 2006, ACM, New York, NY, USA.
9. Colborn T., vom Saal F.S., Soto A.M. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Env. Health Perspect. 1993, 101:378-384.
10. Cramer C.J., Truhlar D.G. AM1-SM2 and PM3-SM3 parametrized SCF solvation models for free energies in aqueous solution. J. Comp. -Aided Mol. Des. 1992, 6:629-666.
11. Crivori P., Poggesi I. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. Eur. J. Med. Chem. 2006, 41:795-808.
12. Cronin M.T.D., Madden J.C. In Silico Toxicology 2010, RSC Publishing, Cambridge, UK.
13. Cronin M.T.D., Dearden J.C., Walker J.D., Worth A.P. Quantitative structure-activity relationships for human health effects: commonalities with other endpoints. Env. Toxicol. Chem. 2003, 22:1829-1843.
14. Custer L.L., Kreatsoulas C., Durham S.K. Predicitve mutagenicity computer models. Computational Toxicology-Risk Assessment for Pharmaceutical and Environmental Chemicals 2007, 391-401. John Wiley & Sons, New York, USA. S. Ekins (Ed.).
15. De Graaf C., Vermeulen N.P.E., Feenstra K.A. Cytochrome P450 in silico: an integrative approach. J. Med. Chem. 2005, 48:2725-2755.
16. Dibb S. Swimming in a sea of estrogens, chemical hormone disrupters. Ecologist 1995, 25:27-31.
17. Dobler, M., 2012. BioX-a versatile molecular-modeling software. (accessed 4.09.14.). http://www.biograf.ch/index.php%3Fid=software.
18. Dobler, M., 2014. Software is part of the VirtualToxLab distribution.
19. Ecker G.F., Chiba P. QSAR studies on drug transporters involved in toxicology. Computational Toxicology-Risk Assessment for Pharmaceutical and Environmental Chemicals 2007, 295-314. John Wiley & Sons, New York, USA. S. Ekins (Ed.).
20. Eid S., Zalewski A., Smieško M., Ernst B., Vedani A. A molecular-modeling toolbox aimed at bridging the gap between medicinal chemistry and computational sciences. Int. J. Mol. Sci. 2013, 14:684-700.
21. Ekins S. Progress in computational toxicology. J. Pharmacol. Toxicol. Methods 2014, 69:115-140.
22. Ekins S. Application of QSAR to enzymes involved in toxicology. Computational Toxicology-Risk Assessment for Pharmaceutical and Environmental Chemicals 2007, 277-294. John Wiley & Sons, New York, USA. S. Ekins (Ed.).
23. Enoch S.J., Cronin M.T.D., Schultz T.W., Madden J.C. Quantitative and mechanistic read across for predicting the skin sensitization potential of alkenes acting via Michael addition. Chem. Res. Toxicol. 2008, 21:513-520.
24. Fischer B. Receptor-mediated effects of chlorinated hydrocarbons. Andrologia 2000, 32:279-283.
25. Green N., Naven R. Early toxicity screening strategies. Curr. Opin. Drug Discov. Dev. 2009, 12:90-97.
26. Guillette L.J., Crain D.A., Rooney A.A., Pickford D.B. Organization versus activation: the role of endocrine disrupting contaminants EDCs during embryonic development in wildlife. Env. Health Perspect. 1995, 103(Suppl. 7):157-164.
27. Gupta S., Kapoor P., Chaudhari K., Gautam A., Kumar R., Raghava G.P.S. In silico approach for predicting toxicity of peptides and proteins. PLoS One 2013, 8:e73957.
28. Helma C. In silico toxicology: the state-of-the-art and strategies to predict human health effects. Curr. Opin. Drug Discov. Dev. 2005, 8:27-31.
29. Humphrey W., Dalke A., Schulten K. VMD - visual molecular dynamics. J. Mol. Graph. 1996, 33-38.
30. Hutter H.P., Wallner P., Moshammer H., Hartl W., Sattelberger R., Lorbeer G., Kundi M. Blood concentrations of polycyclic musks in healthy young adults. Chemosphere 2005, 59(4):487-492.
31. Kavlock R.J., Ankley G., Blancato J., Breen M., Conolly R., Dix D., Houck K., Hubal E., Judson R., Rabinovitz J., Richard A., Setzer R.W., Shah I., Villeneuve D., Weber E. Computational toxicology - a state of the science mini review. Toxicol. Sci. 2008, 103:14-27.
32. Lian G., Chen L., Han L. An evaluation of mathematical models for predicting skin permeability. J. Pharm. Sci. 2008, 97:584-598.
33. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharm. Toxicol. Methods 2000, 44:235-249.
34. McLachlan J.A., Arnold S.F. Environmental estrogens. Am. Sci. 1996, 84:452-461.
35. Merlot C. In silico methods for early toxicity assessment. Curr. Opin. Drug Discov. Dev. 2008, 11:80-85.
36. Metzler M., Pfeiffer E., Hildebrand A.A. Zearalenone and its metabolites as endocrine disrupting chemicals. World Mycotoxin J. 2010, 3:385-401.
37. Muster W., Breidenbach A., Fischer H., Kirchner S., Müller L., Pähler A. Computational toxicology in drug development. Drug Discov. 2008, 13:303-310.
38. Nigsch F., Macaluso N.J.M., Mitchell J.B.O., Zmuidinavicus D. Computational toxicology: an overview of the sources of data and modeling methods. Expert Opin. Drug Metab. Toxicol. 2009, 5:1-14.
39. Okey A.B., Riddick D.S., Harper P.A. The Ah receptor: mediator of the toxicity of 2, 3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Toxicol. Lett. 1994, 70:1-22.
40. Pavan M., Worth A. Publicly accessible QSAR software tools developed by the Joint Research Centre. SAR QSAR Env. Res. 2008, 19:785-799.
41. Piclin N., Pintore M., Wechman C., Roncaglioni A., Benfenati E., Chretien J.R. Ecotoxicity prediction by adaptive fuzzy-partitioning: comparing descriptors computed on 2D and 3D structures. SAR QSAR Env. Res. 2006, 17:225-251.
42. Pineda-Sanabria S., Robertson I.M., Sykes B.D. Structure of trans-resveratrol in complex with the cardiac regulatory protein troponin C. Biochemistry 2011, 50:1309-1320.
43. Rihova B. Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev. 1998, 29:273-289.
44. Roncaglioni A., Toropov A.A., Toropova A.P., Benfenati E. In silico methods to predict drug toxicity. Curr. Opin. Pharmacol. 2013, 13:802-806.
45. Rossato G., Ernst B., Smieško M., Spreafico M., Vedani A. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: an in silico protocol for generating toxicity alerts. ChemMedChem 2010, 5:2088-2101.
46. Schilter B., Benigni R., Boobis A., Chiodini A., Cockburn A., Cronin M.T.D., Lo Piparo E., Modi S., Thiel A., Worth A. Establishing the leval of safety concern for chemicals in food without the need for toxicity testing. Reg. Toxicol. Pharmacol. 2014, 68:275-296.
47. Serafimova R., Todorov M., Pavlov T., Kotov S., Jacob E., Aptula A., Mekenyan O. Identification of the structural requirements of mutagenicity by incorporating molecular flexibility and metabolic activation of chemicals. II. General ames mutagenicity model. Chem. Res. Toxicol. 2007, 20:662-676.
48. Shah F., Greene N. Analysis of Pfizer compounds in EPA's ToxCast chemical-assay space. Chem. Res. Toxicol. 2014, 27:86-98.
49. Schrödinger Software Epik and MacroModel 2012, Schrödinger, LLC, New York, USA.
50. Simon-Hettich B., Rothfuss A., Steger-Hartmann T. Use of computer-assisted prediction of toxic effects of chemical substances. Toxicology 2006, 22:156-162.
51. Singh K.P., Gupta S. In silico prediction of toxicity of non-congeneric industrial chemicals using ensemble-learning based modeling approaches. Toxicol. Appl. Pharmacol. 2014, 275:198-212.
52. Smieško M. Dolina-docking based on a local induced-fit algorithm: application toward small-molecule binding to nuclear receptors. J. Chem. Inf. Model. 2013, 53:1415-1423.
53. Sorrenti V., Di Giacomo C., Aqcuaviva R., Barbagallo I., Bognanno N., Galvano F. Toxicity of ochratoxin A and its modulation by antioxidants: a review. Toxins 2013, 5:1742-1766.
54. Spreafico M., Smieško M., Lill M.A., Ernst B., Vedani A. Mixed-model QSAR at the glucocorticoid receptor: predicting the binding mode and affinity of psychotropic drugs. ChemMedChem 2009, 4:100-109.
55. Takemura H., Shim J.Y., Sayama K., Tsubura A., Zhu B.T., Shimoi K. Characterization of the estrogenic activities of zearalenone and zeranol in vivo and in vitro. J. Steroid Biochem. Mol. Biol. 2007, 103:170-177.
56. Tetko I.V., Tanchuk V.Y. Application of associative neural networks for prediction of lipophilicity in ALOGPS 2.1. J. Chem. Inf. Comput. Sci. 2002, 42:1136-1145.
57. Toropov A.A., Toropova A.P., Raska I., Leszcynska, Leszcynski D. Comprehension of drug toxicity: software and databases. Comput. Biol. Med 2014, 45:20-25.
58. Valerio L.G. In silico toxicology for the pharmaceutical sciences. Toxicol. Appl. Pharmacol. 2009, 241:356-370.
59. Vedani, A. 2014. VirtualToxLab-user and reference manual. Version 5.0. (accessed 04.09.14.). http://www.biograf.ch/downloads/VirtualToxLab.pdf.
60. Vedani A., Dobler M., Smieško M. VirtualToxLab-a platform for estimating the toxic potential of drugs, chemicals and natural products. Toxicol. Appl. Pharmacol. 2012, 261:142-153.
61. Vedani, Dobler M., Lill M.A. Combining protein modeling and 6D-QSAR - simulating the binding of structurally diverse ligands to the estrogen receptor. J. Med. Chem. 2005, 48:3700-3703.
62. Vedani A., Dobler M. 5D-QSAR: the key for simulating induced fit?. J. Med. Chem. 2002, 45:2139-2149.
63. Vedani A., Briem H., Dobler M., Dollinger K., McMasters D.R. Multiple conformation and protonation-state representation in 4D-QSAR: the neurokinin-1 receptor system. J. Med. Chem. 2000, 43:4416-4427.
64. Vedani A., Huhta D.W. A new force field for modeling metalloproteins. J. Am. Chem. Soc. 1990, 112:4759-4767.
65. Veith G.D. On the nature: evolution and future of quantitative structure-activity relationships (QSAR) in toxicology. SAR QSAR Env. Res. 2004, 15:323-330.
66. Veber D.F., Johnson S.R., Cheng H.Y., Smith B.R., Ward K.W., Kopple K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45:2615-2623.
67. Vuorinen A., Odermatt A., Schuster D. In silico methods in the discovery of endocrine-disrupting chemicals. J. Steroid Biochem. Mol. Biol. 2013, 137:18-26.
68. Wang J., Wu Y., Ma C., Fiorin G., Wang J., Pinto L.H., Lamb R.A., Klein M.L., Degrado W.F. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:1315-1321.